• Mithra Announces Shelf Life Extension for Myring™ to 36 Months

    Tuesday August 4th 2020

  • Gilead en Galapagos kondigen positieve Europese CHMP opinie aan voor Jyseleca® (Filgotinib) voor de behandeling van volwassenen met matige tot ernstige reumatoïde artritis

    Friday July 24th 2020

  • Aligos Therapeutics and KU Leuven Announce Collaboration for the Development of a Therapeutic Candidate Targeting Coronavirus

    Thursday July 2nd 2020

  • US Multicenter Study Shows Idylla™ Allows Rapid and Accurate Mutation Testing Results Across Different Laboratory Settings

    Friday June 26th 2020

  • eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through to clinical proof of concept

    Wednesday June 17th 2020

  • Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate

    Thursday June 11th 2020

  • New analyses of Phase 2 Equator Clinical Program support durable efficacy of Filgotinib in Psoriatic Arthritis

    Monday June 8th 2020

  • Filgotinib demonstrates durable efficacy and consistent safety profile at 52 weeks in Finch 1 and 3 studies in rheumatoid arthritis

    Thursday June 4th 2020

  • Your news here?

  • Celyad Provides Update on Allogeneic CAR-T Franchise

    Tuesday June 2nd 2020

  • argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis

    Tuesday May 26th 2020

  • Gilead and Galapagos announce positive topline results of Phase 2B/3 trial of Filgotinib

    Thursday May 21st 2020


Strategic Partners